Mesoblast reports 44% revenue growth and 86% lower quarterly operating cash spend

what happened

Mesoblast has published its activity report for the quarter ended September 30, 2026, according to GlobeNewswire. Net revenues rose 44% and net operating cash spend fell 86% compared with the same period a year earlier. Revenue from RYONCIL for the quarter reached US$28 million, while cash at the end of September stood at US$99 million.

Among operational highlights, the company cited completing enrollment in its pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain. It also held a positive meeting with the FDA on a planned Biologics License Application (BLA) for preventing gastrointestinal bleeding in patients with end-stage heart failure who use a left ventricular assist device. A registration trial of RYONCIL for adults is now enrolling patients.

why it matters

For investors this is mainly a single company's update: revenue growth and lower cash burn matter for judging its path toward self-sufficiency, while trial results and regulatory decisions will shape the outlook for its products. The story sits in a narrow corner of biotech and has little effect on the broader market.

tags

instruments